乳糜瀉藥物市場：按藥物、類型、適應症和最終用戶分類 - 全球預測 2025-2030

乳糜瀉治療市場2023年估值為14.2億美元，預計到2024年將達到15.6億美元，複合年成長率為10.59%，預計到2030年將達到28.7億美元。

乳糜瀉藥物市場研究將分析用於乳糜瀉潛在管理和治療的藥物，乳糜瀉是一種自體免疫疾病，小腸因攝取麩質而受損。範圍包括正在開發的用於緩解症狀、促進黏膜癒合或免疫調節的藥物。這些藥物的需求是由越來越多的乳糜瀉患者、對無麩質生活方式的認知不斷增強以及嚴格的無麩質飲食之外的未滿足的需求所推動的。主要用途包括緩解症狀的藥物和免疫調節療法。最終用途包括醫院、研究機構和專科診所。

市場成長受到醫療保健支出增加、生物技術進步以及患者和醫生意識提高的影響。然而，對非飲食療法的高需求提供了巨大的機會。製藥公司可以利用創新配方和聯合治療。透過增加研發投資並透過與監管機構的夥伴關係加快醫藥品認證過程可以增加市場潛力。挑戰包括嚴格的監管障礙、藥物開發的高成本以及證明新治療方法的長期療效和安全性的綜合臨床試驗資料有限。此外，自體免疫疾病固有的病理生理學複雜性也為藥物設計帶來了複雜性。

為了實現成長，創新應著重於個人化醫療方法，探索治療藥物與遺傳因素之間的相互作用，並透過口服生技藥品等替代藥物傳遞系統來提高患者的依從性。富有洞察力的消費者資料分析可以將研究和開發指導到特定的亞組，從而可能改變標準治療方法。該市場競爭激烈，但未來性，隨著公司尋求投資組合多元化並利用生物技術的進步，預計合併和聯盟將會增加。公司應積極監測監管趨勢，並考慮建立策略聯盟，整合基因組學和藥物輸送系統等新技術，以加速藥物開發平臺。在不斷變化的市場動態中，解決負擔能力和獲取問題對於實現更廣泛的採用和永續仍然至關重要。

市場動態：揭示快速發展的乳糜瀉藥物市場的關鍵市場洞察

乳糜瀉藥物市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

• 市場促進因素
  • 乳糜瀉盛行率增加
  • 對含麩質即食包裝食品的依賴增加
  • 政府和私人組織增加對乳糜瀉認知的支持
• 市場限制因素
  • 治療選擇有限
• 市場機會
  • 活性化研發活動，引進先進的乳糜瀉治療藥物
  • 醫療保健領域的技術進步與現代化
• 市場挑戰
  • 政府對藥品核准的嚴格規定

波特五力：駕馭乳糜瀉藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解乳糜瀉藥物市場的外部影響

外部宏觀環境因素在塑造乳糜瀉治療藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解乳糜瀉治療藥物市場的競爭狀況

對腹腔疾病治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣乳糜瀉藥物市場供應商的績效評估

FPNV 定位矩陣是評估乳糜瀉藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃乳糜瀉藥物市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對乳糜瀉治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

• 市場動態
  • 促進因素
    • 乳糜瀉盛行率增加
    • 食品麩質的食品的依賴增加
    • 增加政府和私部門對乳糜瀉認知的支持
  • 抑制因素
    • 治療選擇有限
  • 機會
    • 活性化研發活動以引進先進的乳糜瀉治療方法
    • 醫療保健領域的技術進步與現代化
  • 任務
    • 政府對藥品核准的嚴格規定
• 市場區隔分析
• 波特五力分析
• PESTEL分析
  • 政治的
  • 經濟
  • 社群
  • 技術的
  • 合法地
  • 環境

第6章 乳糜瀉藥物治療市場

• 一線治療
• 二線治療

第7章乳糜瀉藥物市場：按類型

• 類固醇和免疫抑制劑
• 治療性疫苗
• 維生素和營養食品

第8章乳糜瀉藥物市場（按適應症）

• 厭食症
• 腹脹
• 腹瀉
• 擴張
• 疲勞
• 氣體

第9章乳糜瀉藥物市場：依最終用戶分類

• 臨床研究組織
• 醫院/診所
• 研究/學術機構

第10章美洲乳糜瀉藥物市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第11章亞太乳糜瀉藥物市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第12章歐洲、中東和非洲乳糜瀉藥物市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第13章競爭格局

• 2023 年市場佔有率分析
• FPNV 定位矩陣，2023
• 競爭情境分析
• 戰略分析和建議

公司名單

• AbbVie Inc.
• Adaptive Biotechnologies Corp.
• Almirall SA
• Amgen Inc.
• Amneal Pharmaceuticals LLC
• AMYRA Biotech AG
• Artielle Immunotherapeutics Inc.
• BioLineRx Ltd.
• Bristol Myers Squibb Company
• Calypso Biotech SA
• GlaxoSmithKline PLC
• Glenmark Pharmaceuticals Ltd.
• Inovera Bioscience
• Johnson & Johnson Services, Inc
• Pfizer Inc.
• Precigen Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Vactech Oy
• Zedira GmbH

The Celiac Disease Drugs Market was valued at USD 1.42 billion in 2023, expected to reach USD 1.56 billion in 2024, and is projected to grow at a CAGR of 10.59%, to USD 2.87 billion by 2030.

Celiac Disease Drugs market research involves analyzing pharmaceuticals aimed at managing and potentially treating Celiac disease, an autoimmune disorder where gluten ingestion damages the small intestine. The scope covers drugs that either alleviate symptoms, promote mucosal healing, or are in development for immune modulation. The necessity for these drugs is driven by the increasing prevalence of diagnosed Celiac cases, expanding gluten-free lifestyle awareness, and the unmet need beyond a strict gluten-free diet. Key applications include pharmaceuticals for symptomatic relief and immune modulation therapies. End-use scopes involve hospitals, research institutions, and specialty clinics.

Market growth is influenced by rising healthcare expenditures, advancements in biotechnology, and heightened patient and physician awareness. However, substantial opportunities lie in the high demand for non-dietary therapeutics. Pharmaceutical companies can capitalize on innovative drug formulations and combination therapies. Expanding R&D investments and expediting drug approval processes through collaborative partnerships with regulatory authorities could enhance market potential. Challenges include stringent regulatory hurdles, high costs of drug development, and limited comprehensive clinical trial data demonstrating long-term efficacy and safety of emerging treatments. Additionally, the inherent complexity of autoimmune pathophysiology poses complications in drug design.

For growth, innovation should focus on personalized medicine approaches, exploring genetic component interactions with therapeutics, and enhancing patient compliance through alternative drug delivery systems such as oral biologics. Insightful consumer data analytics could redirect R&D towards specific subgroups, potentially changing standard care practices. The market's nature is competitive yet promising, with increased mergers and partnerships anticipated as firms strive to diversify portfolios and leverage biotechnological advancements. Businesses should actively monitor regulatory trends and consider strategic alliances to integrate emerging technologies like genomics and drug delivery systems to accelerate drug development pipelines. Addressing affordability and access remains crucial for wider adoption and sustainability in evolving market dynamics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Celiac Disease Drugs Market

The Celiac Disease Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growth in prevalence of celiac disease
  • Rising dependence of gluten containing and ready-to-eat packaged food
  • Increase government and private organizations support towards celiac disease awareness
• Market Restraints
  • Restricted availability of treatment options
• Market Opportunities
  • Rising R&D activities to introduce advanced celiac disease drugs
  • Technological advancements and increasing modernization in the healthcare sector
• Market Challenges
  • Strict government regulations for drug approval

Porter's Five Forces: A Strategic Tool for Navigating the Celiac Disease Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Celiac Disease Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Celiac Disease Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Celiac Disease Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Celiac Disease Drugs Market

A detailed market share analysis in the Celiac Disease Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Celiac Disease Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Celiac Disease Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Celiac Disease Drugs Market

A strategic analysis of the Celiac Disease Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Celiac Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptive Biotechnologies Corp., Almirall SA, Amgen Inc., Amneal Pharmaceuticals LLC, AMYRA Biotech AG, Artielle Immunotherapeutics Inc., BioLineRx Ltd., Bristol Myers Squibb Company, Calypso Biotech SA, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Inovera Bioscience, Johnson & Johnson Services, Inc, Pfizer Inc., Precigen Inc., Sanofi S.A., Takeda Pharmaceutical Co. Ltd., Vactech Oy, and Zedira GmbH.

Market Segmentation & Coverage

This research report categorizes the Celiac Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug, market is studied across First Line of Treatment and Second Line of Treatment.
• Based on Type, market is studied across Steroids & Immunosuppressive Drugs, Therapeutic Vaccines, and Vitamins & Dietary Supplements.
• Based on Indication, market is studied across Anorexia, Bloating, Diarrhea, Distension, Fatigue, and Gas.
• Based on End-User, market is studied across Clinical Research Organizations, Hospitals & Clinics, and Research & Academic Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growth in prevalence of celiac disease
    • 5.1.1.2. Rising dependence of gluten containing and ready-to-eat packaged food
    • 5.1.1.3. Increase government and private organizations support towards celiac disease awareness
  • 5.1.2. Restraints
    • 5.1.2.1. Restricted availability of treatment options
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising R&D activities to introduce advanced celiac disease drugs
    • 5.1.3.2. Technological advancements and increasing modernization in the healthcare sector
  • 5.1.4. Challenges
    • 5.1.4.1. Strict government regulations for drug approval
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Celiac Disease Drugs Market, by Drug

• 6.1. Introduction
• 6.2. First Line of Treatment
• 6.3. Second Line of Treatment

7. Celiac Disease Drugs Market, by Type

• 7.1. Introduction
• 7.2. Steroids & Immunosuppressive Drugs
• 7.3. Therapeutic Vaccines
• 7.4. Vitamins & Dietary Supplements

8. Celiac Disease Drugs Market, by Indication

• 8.1. Introduction
• 8.2. Anorexia
• 8.3. Bloating
• 8.4. Diarrhea
• 8.5. Distension
• 8.6. Fatigue
• 8.7. Gas

9. Celiac Disease Drugs Market, by End-User

• 9.1. Introduction
• 9.2. Clinical Research Organizations
• 9.3. Hospitals & Clinics
• 9.4. Research & Academic Institutes

10. Americas Celiac Disease Drugs Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Celiac Disease Drugs Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Celiac Disease Drugs Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Adaptive Biotechnologies Corp.
• 3. Almirall SA
• 4. Amgen Inc.
• 5. Amneal Pharmaceuticals LLC
• 6. AMYRA Biotech AG
• 7. Artielle Immunotherapeutics Inc.
• 8. BioLineRx Ltd.
• 9. Bristol Myers Squibb Company
• 10. Calypso Biotech SA
• 11. GlaxoSmithKline PLC
• 12. Glenmark Pharmaceuticals Ltd.
• 13. Inovera Bioscience
• 14. Johnson & Johnson Services, Inc
• 15. Pfizer Inc.
• 16. Precigen Inc.
• 17. Sanofi S.A.
• 18. Takeda Pharmaceutical Co. Ltd.
• 19. Vactech Oy
• 20. Zedira GmbH

LIST OF FIGURES

• FIGURE 1. CELIAC DISEASE DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. CELIAC DISEASE DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CELIAC DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CELIAC DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CELIAC DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CELIAC DISEASE DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY FIRST LINE OF TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SECOND LINE OF TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY STEROIDS & IMMUNOSUPPRESSIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY VITAMINS & DIETARY SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ANOREXIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BLOATING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DIARRHEA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTENSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY FATIGUE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GAS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 39. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 61. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 65. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 134. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. POLAND CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 150. POLAND CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. POLAND CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. POLAND CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. QATAR CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 154. QATAR CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 155. QATAR CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 156. QATAR CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 193. CELIAC DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 194. CELIAC DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023